U.S. Patent No. 6,873,940 Survives Review with All Claims Intact
Suffern, N.Y. – September 26, 2018 – General Patent Corporation (GPC), a leading intellectual property licensing firm, announced today that its subsidiary, Kamatani Cloud LLC (Kamatani Cloud), has prevailed on all 41 claims challenged in an inter partes review (IPR) initiated by Unified Patents, Inc.
Federal Circuit Misapplies Rule 19 Involuntary Joinder Requirement in Patent Cases
Suffern, N.Y. – October 17, 2017 – General Patent Corporation (GPC), a leading patent licensing firm, announced today that its subsidiary, Bradium Technologies LLC (Bradium), has settled its patent infringement litigation with Microsoft.
Suffern, N.Y. – July 12, 2016 – Fractal Heatsink Technologies LLC, an R&D company focusing on developing innovative fractal heatsink technologies, was recently awarded U.S. Patent No. 9,228,785 - Fractal Heat Transfer Device (the “’785 Patent”).
Newly Granted Patents Further Strengthen the Importance of IPT’s Image Processing IP Portfolio
Shanahan Brings Wealth of Corporate and Law Firm IP Licensing
and Litigation Experience to General Patent
Newly Issued Patent Directed to Tracking a Target Using an Image Processing System
New Patents Further Develop IP Related to CD81 and Human Glucokinase
Suffern, N.Y. –August 27, 2014 – Ryogen LLC, an R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded two new patents, bringing the total number of its issued U.S. Patents to 34.
U.S. Patent No. 8,795,959 titled “Isolated glucokinase genomic polynucleotide fragments from chromosome 7” was issued August 5, 2014. This patent continues the theme of a previously issued Ryogen patent, U.S. Patent No. 8,313,899. The new patent claims a method of detection of specified sequences from polynucleotide sequence which encodes a protein that has human glucokinase activity. Glucokinase plays an important role in the regulation of carbohydrate metabolism. It serves as a glucose sensor of the insulin-producing pancreatic cells, controls the conversion of glucose to glycogen in the liver, and regulates hepatic glucose production. Mutations in the gene for this enzyme are associated with different forms of Diabetes and Hypoglycemia.
New Patents Build on Previous Patents Related to TSSC4 and hMDM2 Homolog
Suffern, N.Y. – July 29, 2014 – Ryogen LLC, an R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded two new patents this month, bringing the total number of its issued U.S. Patents to 32.
U.S. Patent No. 8,765,928 entitled “Identification of isolated genomic nucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (TSSC4) and variants thereof” was issued on July 1, 2014. The TSSC4 gene is one of several tumor-suppressing fragments on chromosome 11, alterations to which have been associated with some cancers. Ryogen’s portfolio includes U.S. Patent No. 8,722,865 directed to TSSC4. This new patent claims a further method of identifying variants in corresponding DNA or RNA polynucleotides.
GAO RFID Takes a License under the Leighton Technologies Patents
As a result of the settlement, GAO has licensed Leighton Technologies’ portfolio of six “Contactless Cards” and related technology patents at a 5% royalty rate. The Leighton patent portfolio covers a hot lamination process for the manufacture of contact and contactless smart cards and RFID cards.